Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid Search-Projection pursuit regression method

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Du, Hongying ^a,b   Hu, Zhide ^b   Bazzoli, Andrea ^a   Zhang, Yang ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ARTICLE; BEST MULTILINEAR REGRESSION MODEL; CONTROLLED STUDY; DRUG DESIGN; DRUG TARGETING; PREDICTION; PROJECTION PURSUIT REGRESSION MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; HUMAN; IC 50; PRINCIPAL COMPONENT ANALYSIS; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; HUMANS; INHIBITORY CONCENTRATION 50; LINEAR MODELS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN-TYROSINE KINASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79960629926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022367     Document Type: Article

References (59)

1. Ullrich A, Schlessinger J, (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212.
2. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G, (1998) Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. Febs Letters 425: 145-150.
3. Wells A, (1999) EGF receptor. International Journal of Biochemistry & Cell Biology 31: 637-643.
4. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology 2: 127-137.
5. Hsuan JJ, (1993) Oncogene regulation by growth-factors. Anticancer Research 13: 2521-2532.
6. Soler C, Beguinot L, Carpenter G, (1994) Individual epidermal growth-factor receptor autophosphorylation sites do not stringently define association motifs for several SH2-containing proteins. Journal of Biological Chemistry 269: 12320-12324.
7. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS, (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology 8: 1197-1206.
8. Toyoshima E, Ohsaki Y, Nishigaki Y, Fujimoto Y, Kohgo Y, et al. (2001) Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. Lung Cancer 31: 193-202.
9. Gross ME, Zorbas MA, Danels YJ, Garcia R, Gallick GE, et al. (1991) Cellular growth-response to epidermal growth-factor in colon-carcinoma cells with an amplified epidermal growth-factor receptor derived from a familial adenomatous polyposis patient. Cancer Research 51: 1452-1459.
10. Damstrup L, Rygaard K, Spangthomsen M, Poulsen HS, (1992) Expression of the epidermal growth-factor receptor in human small-cell lung-cancer cell-lines. Cancer Research 52: 3089-3093.
11. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, Henegouwen P, et al. (2009) Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Current Cancer Drug Targets 9: 748-760.
12. Bridges AJ, (1999) The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Current Medicinal Chemistry 6: 825-843.
13. Boschelli DH, (1999) Small molecule inhibitors of receptor tyrosine kinases. Drugs of the Future 24: 515-537.
14. Ma XH, Wang R, Tan CY, Jiang YY, Lu T, et al. (2010) Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. Molecular Pharmaceutics 7: 1545-1560.
15. Abouzid K, Shouman S, (2008) Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. Bioorganic & Medicinal Chemistry 16: 7543-7551.
16. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, et al. (2003) Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). Journal of Medicinal Chemistry 46: 49-63.
17. Pawar VG, Sos ML, Rode HB, Rabiller M, Heynck S, et al. (2010) Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. Journal of Medicinal Chemistry 53: 2892-2901.
18. Klutchko SR, Hamby JM, Boschelli DH, Wu ZP, Kraker AJ, et al. (1998) 2-substituted aminopyrido 2,3-d pyrimidin-7(8H) ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. Journal of Medicinal Chemistry 41: 3276-3292.
19. Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, et al. (2004) Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. Journal of Pharmacology and Experimental Therapeutics 311: 502-509.
20. Thompson AM, Bridges AJ, Fry DW, Kraker AJ, Denny WA, (1995) Tyrosine kinase inhibitors. 7. 7-amino-4-(phenylamino)pyrido 4,3-d pyrimidines and 7-amino-4- (phenylmethyl)amino pyrido 4,3-d pyrimidines- a new class of inhibitors of the tyrosine kinase-activity of the epidermal growth-factor receptor. Journal of Medicinal Chemistry 38: 3780-3788.
21. Ding K, Lu YP, Nikolovska-Coleska Z, Wang GP, Qiu S, et al. (2006) Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. Journal of Medicinal Chemistry 49: 3432-3435.
22. Li N, Thompson S, Schultz DC, Zhu WL, Jiang HL, et al. (2010) Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. Plos One 5: e10126-e10129.
23. Nunez MB, Maguna FP, Okulik NB, Castro EA, (2004) QSAR modeling of the MAO inhibitory activity of xanthones derivatives. Bioorganic & Medicinal Chemistry Letters 14: 5611-5617.
24. Hansch C, Verma RP, (2009) Overcoming tumor drug resistance with C2-modified 10-deacetyl-7-propionyl cephalomannines: A QSAR study. Molecular Pharmaceutics 6: 849-860.
25. Mandal AS, Roy K, (2009) Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives. European Journal of Medicinal Chemistry 44: 1509-1524.
26. Liu FP, Liang YZ, Cao CZ, (2006) QSPR modeling of thermal conductivity detection response factors for diverse organic compound. Chemometrics and Intelligent Laboratory Systems 81: 120-126.
27. Liu HX, Gramatica P, (2007) QSAR study of selective ligands for the thyroid hormone receptor beta. Bioorganic & Medicinal Chemistry 15: 5251-5261.
28. Verma RP, Hansch C, (2010) QSAR modeling of taxane analogues against colon cancer. Eur J Med Chem 45: 1470-1477.
29. Pasha FA, Muddassar M, Srivastava AK, Cho SJ, (2010) In silico QSAR studies of anilinoquinolines as EGFR inhibitors. Journal of Molecular Modeling 16: 263-277.
30. Vema A, Panigrahi SK, Rambabu G, Gopalakrishnan B, Sarma J, et al. (2003) Design of EGFR kinase inhibitors: A ligand-based approach and its confirmation with structure-based studies. Bioorganic & Medicinal Chemistry 11: 4643-4653.
31. Szántai-Kis C, Kövesdi I, Eros D, Bánhegyi P, Ullrich A, et al. (2006) Prediction oriented QSAR modelling of EGFR inhibition. Current Medicinal Chemistry 13: 277-287.
32. La Motta C, Sartini S, Tuccinardi T, Nerini E, Da Settimo F, et al. (2009) Computational studies of epidermal growth factor receptor: Docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies. Journal of Medicinal Chemistry 52: 964-975.
33. Shi WM, Shen Q, Kong W, Ye BX, (2007) QSAR analysis of tyrosine kinase inhibitor using modified ant colony optimization and multiple linear regression. European Journal of Medicinal Chemistry 42: 81-86.
34. Friedman JH, Stuetzle W, (1981) Projection pursuit regression. Journal of the American Statistical Association 76: 817-823.
35. Huber PJ, (1985) Projection pursuit. Annals of Statistics 13: 435-475.
36. Donoho D, Johnstone I, Rousseeuw P, Stahel W, (1985) Projection pursuit- Discussion. Annals of Statistics 13: 496-500.
37. Rewcastle GW, Denny WA, Bridges AJ, Zhou HR, Cody DR, et al. (1995) Tyrosine kinase inhibitors. 5. synthesis and structure- activity- relationships for 4- (phenylmethyl)amino- quinazolines and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding-site inhibitors of the tyrosine kinase domain of the epidermal growth-factor receptor. Journal of Medicinal Chemistry 38: 3482-3487.
38. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, et al. (1996) Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. Journal of Medicinal Chemistry 39: 267-276.
39. Rewcastle GW, Palmer BD, Thompson AM, Bridges AJ, Cody DR, et al. (1996) Tyrosine kinase inhibitors. 10. Isomeric 4- (3-bromophenyl)amino pyrido d-pyrimidines are potent ATP-binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. Journal of Medicinal Chemistry 39: 1823-1835.
40. Rewcastle GW, Bridges AJ, Fry DW, Rubin JR, Denny WA, (1997) Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido 5,4-d pyrimidines designed as inhibitors of the epidermal growth factor receptor. Journal of Medicinal Chemistry 40: 1820-1826.
41. Thompson AM, Murray DK, Elliott WL, Fry DW, Nelson JA, et al. (1997) Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4- (3-bromophenyl)amino pyrido 4,3-d pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry 40: 3915-3925.
42. ISIS Draw2. 3 MDLInformation Systems, Inc (1990-2000).
43. HyperChem, Release 6.0 for Windows, Hypercube, Inc., 2000.
44. Todeschini R, Consonni V, Mauri A, Pavan M, (2006) DRAGONs Software for the calculation of molecular descriptors, version 5.4 for Windows. Milan, Italy Talete srl.
45. Katritzky AR, Lobanov VS, Karelson M, (1995) CODESSA Version 2.0 Reference Manual Gainesville Florida University of Florida.
46. Todeschini R, Consonni V, (2000) Handbook of Molecular Descriptors; Wiley-VCH. Weinheim, Germany.
47. Katritzky AR, Lobanov VS, Karelson M, (1995) CODESSA: Training Manual. Gainesville, Florida University of Florida.
48. Du HY, Wang J, Hu ZD, Yao XJ, Zhang XY, (2008) Prediction of fungicidal activities of rice blast disease based on least-squares support vector machines and project pursuit regression. Journal of Agricultural and Food Chemistry 56: 10785-10792.
49. Birattari M, Bontempi G, (2003) R manuals, The R Development Core Team.
50. Strouf O, (1986) Chemical Pattern Recognition New York Wiley.
51. Weast RC, (1974) Handbook of Chemistry and Physics. Cleveland OH CRC Press.
52. Fukui K, (1975) Theory of Orientation nad Stereoselection Berlin Springer-Verlag.
53. Consonni V, Todeschini R, Pavan M, (2002) Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D molecular descriptors. Journal of Chemical Information and Computer Sciences 42: 682-692.
54. Basak SC, Mills D, Hawkins DM, (2008) Predicting allergic contact dermatitis: a hierarchical structure-activity relationship (SAR) approach to chemical classification using topological and quantum chemical descriptors. Journal of Computer-Aided Molecular Design 22: 339-343.
55. Stamos J, Sliwkowski MX, Eigenbrot C, (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. Journal of Biological Chemistry 277: 46265-46272.
56. Delano WL, (2002) The PyMol Molecular Graphics System Delano Scientific. San Carlos, CA, USA DeLano Scientific.
57. The R Project for Statistical Computing. http://www.r-project.org/ (Accessed May 21, 2010).
58. Puzyn T, Leszczynski J, Cronin MT, (2010) Recent Advances in QSAR Studies Methods and Applications: Springer Dordrecht Heidelberg London New York.
59. Du HY, Wang J, Zhang XY, Hu ZD, (2008) A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site. European Journal of Medicinal Chemistry 43: 2861-2869.